Nerve Growth Factor and Brain-Derived Neurotrophic Factor as Potential Biomarkers of Mirabegron Efficacy in Patients with Overactive Bladder Syndrome.
BDNF
Mirabegron
NGF
Neurotrophins
Overactive bladder
Journal
International urogynecology journal
ISSN: 1433-3023
Titre abrégé: Int Urogynecol J
Pays: England
ID NLM: 101567041
Informations de publication
Date de publication:
18 May 2024
18 May 2024
Historique:
received:
18
02
2024
accepted:
09
04
2024
medline:
18
5
2024
pubmed:
18
5
2024
entrez:
18
5
2024
Statut:
aheadofprint
Résumé
Overactive Bladder Syndrome (OAB) significantly impacts quality of life, necessitating improved diagnostic tools and treatment monitoring. This study explores the potential of neurotrophins, nerve growth factor (NGF), and brain-derived neurotrophic factor (BDNF) as urinary biomarkers in patients with OAB undergoing mirabegron therapy, a β3-adrenergic agonist. This investigation is aimed at providing insights into the potential of neurotrophins to enhance OAB diagnosis and assess treatment efficacy. Urinary NGF and BDNF levels were measured in 15 healthy controls and 30 patients with OAB. Patients were treated with mirabegron 50 mg once daily. Urinary NGF and BDNF levels were measured by enzyme-linked immunosorbent assay method and normalized by urinary creatinine levels (NGF/Cre and BDNF/Cre). The urinary NGF/Cre and BDNF/Cre levels were compared between controls and patients with OAB and subsequently at baseline and 3 months after mirabegron treatment. Treatment efficacy was assessed with the Indevus Urgency Severity Scale (IUSS) questionnaire. Urinary NGF/Cre and BDNF/Cre levels were significantly higher in patients with OAB than in the controls (p < 0.001 and p = 0.03 respectively). Moreover, NGF/Cre and BDNF/Cre levels significantly decreased post-mirabegron treatment (p < 0.001 and p = 0.005 respectively). Patients with improvement of OAB symptoms after treatment showed lower levels of NGF/Cre at the 3-month evaluation than those with no improvement (p = 0.05). Although both NGF/Cre and BDNF/Cre levels were significantly decreased after mirabegron treatment, only NGF/Cre levels were associated with treatment response.
Identifiants
pubmed: 38761233
doi: 10.1007/s00192-024-05809-0
pii: 10.1007/s00192-024-05809-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The International Urogynecological Association.
Références
Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37–49.
doi: 10.1016/S0090-4295(02)02243-4
pubmed: 12559262
Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36.
doi: 10.1007/s00345-002-0301-4
pubmed: 12811491
Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21(1):5–26.
doi: 10.1007/s00192-009-0976-9
pubmed: 19937315
Drake MJ. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013. Neurourol Urodyn. 2014;33(5):622–4.
doi: 10.1002/nau.22609
pubmed: 24838519
McGuire E. Bladder instability and stress incontinence. Neurourol Urodyn. 1988;7(6):563–7.
doi: 10.1002/nau.1930070605
Bates CP, Bradley WE, Glen ES, et al. Third Report on the Standardisation of Terminology of Lower Urinary Tract Function: procedures related to the evaluation of micturition: pressure-flow relationships. Residual urine. Br J Urol. 1980;52(5):348–50.
doi: 10.1111/j.1464-410X.1980.tb03058.x
Robinson D, Thiagamoorthy G, Cardozo L. A drug safety evaluation of mirabegron in the management of overactive bladder. Expert Opin Drug Saf. 2016;15(5):689–96.
doi: 10.1517/14740338.2016.1165663
pubmed: 26980445
Mirabegron. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Accessed 2 September 2023. Available from: http://www.ncbi.nlm.nih.gov/books/NBK547887/
Yoshida M, Masunaga K, Nagata T, Yono M, Homma Y. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: pathophysiology and pharmacotherapy of overactive bladder. J Pharmacol Sci. 2010;112(2):128–34.
doi: 10.1254/jphs.09R12FM
pubmed: 20134115
Cruz CD. Neurotrophins in bladder function: what do we know and where do we go from here? Neurourol Urodyn. 2014;33(1):39–45.
doi: 10.1002/nau.22438
pubmed: 23775873
Ochodnicky P, Cruz CD, Yoshimura N, Cruz F. Neurotrophins as regulators of urinary bladder function. Nat Rev Urol. 2012;9(11):628–37.
doi: 10.1038/nrurol.2012.178
pubmed: 23045265
Ochodnický P, Cruz CD, Yoshimura N, Michel MC. Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target. Neurourol Urodyn. 2011;30(7):1227–41.
doi: 10.1002/nau.21022
pubmed: 21520250
Nixon A, Colman S, Sabounjian L, et al. A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol. 2005;174(2):604–7. https://doi.org/10.1097/01.ju.0000165461.38088.7b .
doi: 10.1097/01.ju.0000165461.38088.7b
pubmed: 16006914
Steers WD. Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol. 2002;4(Suppl 4):S7–18.
pubmed: 16986023
pmcid: 1476015
Coelho A, Oliveira R, Antunes-Lopes T, Duarte Cruz C. Partners in crime: NGF and BDNF in visceral dysfunction. Curr Neuropharmacol. 2019;17(11):1021–38. https://doi.org/10.2174/1570159X17666190617095844 .
doi: 10.2174/1570159X17666190617095844
pubmed: 31204623
pmcid: 7052822
Yuk SM, Shin JH, Song KH, Na YG, Lim JS, Sul CK. Expression of brain derived-neurotrophic factor and granulocyte-colony stimulating factor in the urothelium: relation with voiding function. BMC Urol. 2015;15:37. https://doi.org/10.1186/s12894-015-0036-3
doi: 10.1186/s12894-015-0036-3
pubmed: 25951823
pmcid: 4436171
Cheng C, Li Q, Lin G, Opara EC, Zhang Y. Neurobiological insights into lower urinary tract dysfunction: evaluating the role of brain-derived neurotrophic factor. Am J Clin Exp Urol. 2023;11(6):559–77
pubmed: 38148930
pmcid: 10749380
Kashyap MP, Pore SK, de Groat WC, Chermansky CJ, Yoshimura N, Tyagi P. BDNF overexpression in the bladder induces neuronal changes to mediate bladder overactivity. Am J Physiol Renal Physiol. 2018;315(1):F45–56.
doi: 10.1152/ajprenal.00386.2017
pubmed: 29092846
Tsiapakidou S, Apostolidis A, Pantazis K, Grimbizis GF, Mikos T. The use of urinary biomarkers in the diagnosis of overactive bladder in female patients. A systematic review and meta-analysis. Int Urogynecol J. 2021;32(12):3143–55.
doi: 10.1007/s00192-021-04945-1
pubmed: 34363496
Liu HT, Chen CY, Kuo HC. Urinary nerve growth factor in women with overactive bladder syndrome. BJU Int. 2011;107(5):799–803.
doi: 10.1111/j.1464-410X.2010.09585.x
pubmed: 20804479
Antunes-Lopes T, Pinto R, Barros SC, et al. Urinary neurotrophic factors in healthy individuals and patients with overactive bladder. J Urol. 2013;189(1)):359–65. https://doi.org/10.1016/j.juro.2012.08.187
doi: 10.1016/j.juro.2012.08.187
pubmed: 23174241
Suh YS, Ko KJ, Kim TH, et al. Urinary nerve growth factor as a potential biomarker of treatment outcomes in overactive bladder patients. Int Neurourol J. 2017;21(4):270–81.
doi: 10.5213/inj.1732794.397
pubmed: 29298466
pmcid: 5756815
Sağır S, Bayrak Ö, Şen H, Kul S, Erturhan S, Seçkiner İ. Correlation between the NGF levels and questionnaire forms in patients receiving antimuscarinic treatment and those receiving onabotulinum toxin-A injection. Turk J Urol. 2021;47(3):223–8.
doi: 10.5152/tud.2020.20432
pubmed: 33135996
Birder LA, Wolf-Johnston AS, Sun Y, Chai TC. Alteration in TRPV1 and Muscarinic (M3) receptor expression and function in idiopathic overactive bladder urothelial cells. Acta Physiol (Oxf). 2013;207(1):123–9.
doi: 10.1111/j.1748-1716.2012.02462.x
pubmed: 22691178